Deutsche Bank Appointed as Depositary Bank for the Sponsored American Depositary Receipt Program of Connect Biopharma Holdings Limited

Rhea-AI Summary

Deutsche Bank has been appointed as the depositary bank for the American Depositary Receipt (ADR) program of Connect Biopharma Holdings Limited, listed on NASDAQ under the symbol CNTB. This appointment, effective March 23, 2021, will enable Deutsche Bank to provide dedicated client service and investor relations support to enhance the program's future success. Connect Biopharma is focused on developing therapies for T cell-driven inflammatory diseases and employs advanced cellular assays in its research efforts.

Positive

• Deutsche Bank appointed as depositary bank for Connect Biopharma's NASDAQ-listed ADR program, showing confidence in the company's growth.
• The appointment aims to enhance investor relations and client service, potentially increasing investor interest.

Negative

• None.

Deutsche Bank announced today its appointment as depositary bank for the Nasdaq-listed American Depositary Receipt program of Connect Biopharma Holdings Limited.

Connect Biopharma Holdings Limited (NASDAQ: CNTB), is a global clinical-stage biopharmaceutical company developing therapies for the treatment of T cell- driven inflammatory diseases with a core expertise in the use of functional cellular assays with T cells to screen discovering potent product candidates against immune targets.*

“We are pleased to be appointed as depositary bank for Connect Biopharma Holdings Limited’s NASDAQ-listed Level III American Depositary Receipt program,” said Daniel Clark, Global Head of Depositary Receipts at Deutsche Bank. “We look forward to providing dedicated client service and investor relations support to help drive the program’s future success.”

In addition to specializing in administering cross-border equity structures such as New York Shares and American and Global Depositary Receipts, Deutsche Bank provides corporates, financial institutions, hedge funds and supranational agencies around the world with trustee, agency, escrow and related services.

Deutsche Bank offers a very broad range of services for diverse products, from complex securitizations and project finance to syndicated loans, debt exchanges and restructurings.

* This information was provided by Connect Biopharma Holdings Limited (March 2021).

Depositary Receipt Information
Country			China (Cayman Islands incorporated)
Custodian Bank			Deutsche Bank AG, Hong Kong Branch
Effective Date			March 23, 2021
Level III ADR
CUSIP			207523 101
ISIN			US2075231017
Symbol			CNTB
Exchange			NASDAQ
Current Ratio			1 ADS: 1 Class A ordinary share
Eligibility			DTC

Depositary Receipt Contacts
Head of Depositary Receipts		New Business Development
Daniel Clark		William Ng
Tel: +44 (0) 20 7541 6888		Tel: +852 2203 7889
www.adr.db.com		Markets Distribution
adr@db.com		London
		Tel: +44 (0) 20 7547 6500
gtb.db.com		New York
		Tel: +1 212 250 9100
		Hong Kong
		Tel: +852 2203 7854

Deutsche Bank provides commercial and investment banking, retail banking, transaction banking and asset and wealth management products and services to corporations, governments, institutional investors, small and medium-sized businesses, and private individuals. Deutsche Bank is Germany’s leading bank, with a strong position in Europe and a significant presence in the Americas and Asia Pacific.

The Depositary Receipts have been registered pursuant to the US Securities Act of 1933 (the "Act"). The investment or investment service which is the subject of this notice is not available to retail clients as defined by the UK Financial Conduct Authority. This notice has been approved and/or communicated by Deutsche Bank AG New York. The services described in this notice are provided by Deutsche Bank Trust Company Americas (Deutsche Bank) or by its subsidiaries and/or affiliates in accordance with appropriate local registration and regulation. Deutsche Bank is providing the attached notice strictly for information purposes and makes no claims or statement, nor does it warrant or in any way represent, as to the accuracy or completeness of the details contained herein or therein. This announcement appears as a matter of record only. Neither this announcement nor the information contained herein constitutes an offer or solicitation by Deutsche Bank or any other issuer or entity for the purchase or sale of any securities nor does it constitute a solicitation to any person in any jurisdiction where solicitation would be unlawful. No part of this notice may be copied or reproduced in any way without the prior written consent of Deutsche Bank. Past results are not an indication of future performance. Copyright© March 2021 Deutsche Bank AG. All rights reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210325005967/en/

FAQ

What is the significance of Deutsche Bank being appointed as the depositary bank for Connect Biopharma?

Deutsche Bank's appointment is significant as it indicates confidence in Connect Biopharma's growth potential and aims to improve investor relations for its NASDAQ-listed ADR program.

When did Deutsche Bank's role as depositary bank for Connect Biopharma become effective?

The role as depositary bank for Connect Biopharma became effective on March 23, 2021.

What is the stock symbol of Connect Biopharma Holdings Limited?

The stock symbol for Connect Biopharma Holdings Limited is CNTB, and it is listed on NASDAQ.

What kind of therapies does Connect Biopharma develop?

Connect Biopharma develops therapies targeting T cell-driven inflammatory diseases, utilizing advanced functional cellular assays.